Pelitrexol

Drug Profile

Pelitrexol

Alternative Names: AG 2037

Latest Information Update: 12 Aug 2008

Price : $50

At a glance

  • Originator Pfizer
  • Class Antineoplastics; Small molecules; Thiophenes
  • Mechanism of Action Phosphoribosylglycinamide formyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Colorectal cancer; Non-small cell lung cancer

Most Recent Events

  • 12 Aug 2008 No development reported - Phase-II for Colorectal cancer in USA (IV)
  • 12 Aug 2008 No development reported - Phase-II for Non-small cell lung cancer in USA (IV)
  • 02 Aug 2006 Pfizer has completed two phase II trials in colorectal and non-small cell lung cancer in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top